VanEck Associates’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Buy
17,887
+11,354
+174% +$1.39M ﹤0.01% 1003
2026
Q1
$744K Sell
6,533
-29,983
-82% -$4.19M ﹤0.01% 1124
2025
Q4
$5.98M Sell
36,516
-3,231
-8% -$506K ﹤0.01% 729
2025
Q3
$5.31M Sell
39,747
-3,734
-9% -$454K ﹤0.01% 745
2025
Q2
$5.41M Sell
43,481
-734
-2% -$93.4K 0.01% 698
2025
Q1
$5.63M Buy
44,215
+1,989
+5% +$306K 0.01% 664
2024
Q4
$6.08M Buy
42,226
+3,066
+8% +$440K 0.01% 614
2024
Q3
$5.38M Sell
39,160
-6,025
-13% -$864K 0.01% 611
2024
Q2
$5.7M Buy
45,185
+404
+0.9% +$63.3K 0.01% 541
2024
Q1
$8.24M Sell
44,781
-1,755
-4% -$334K 0.01% 455
2023
Q4
$8.37M Sell
46,536
-8,016
-15% -$1.25M 0.02% 416
2023
Q3
$8.68M Sell
54,552
-1,611
-3% -$263K 0.02% 368
2023
Q2
$7.94M Sell
56,163
-4,644
-8% -$745K 0.02% 394
2023
Q1
$10.2M Sell
60,807
-4,206
-6% -$750K 0.02% 345
2022
Q4
$11M Buy
65,013
+16,660
+34% +$3.02M 0.03% 319
2022
Q3
$9.05M Buy
48,353
+42,506
+727% +$8.96M 0.03% 329
2022
Q2
$950K Sell
5,847
-648
-10% -$102K ﹤0.01% 801
2022
Q1
$1.22M Buy
6,495
+2,422
+59% +$460K ﹤0.01% 799
2021
Q4
$1.08M Buy
4,073
+636
+19% +$171K ﹤0.01% 832
2021
Q3
$993K Sell
3,437
-16
-0.5% -$4.11K ﹤0.01% 809
2021
Q2
$689K Buy
3,453
+137
+4% +$26.6K ﹤0.01% 867
2021
Q1
$645K Buy
+3,316
New +$680K ﹤0.01% 813

Other funds holding RGEN

VanEck Associates's RGEN Position: Q2 2026 in Review

VanEck Associates increased its Repligen (RGEN) stake by 174% in Q2 2026, buying an estimated $1.39M and bringing the position to 17,887 shares worth $2.44M. The position accounts for ﹤0.01% of the portfolio, ranked #1003.

VanEck Associates first reported a position in RGEN in Q1 2021 and has held it in 22 quarters since. The position peaked at $11M in Q4 2022. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • VanEck Associates held 17,887 shares of Repligen worth $2.44M as of Q2 2026.
  • VanEck Associates bought 11,354 Repligen shares in Q2 2026, an estimated $1.39M.
  • Repligen made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #1003 holding.
  • VanEck Associates first reported a position in Repligen in Q1 2021 and has held it in 22 quarters since.
  • VanEck Associates's Repligen position peaked at $11M in Q4 2022.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.